This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Characterization and functional evidence for Orf2 of Streptomyces sp. 139 as a novel dipeptidase E
Applied Microbiology and Biotechnology Open Access 08 May 2024
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alam J, Jantan I, Bukhari SNA . Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother 2017; 92: 615–633.
Bartok B, Firestein GS . Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233–255.
Brennan FM, McInnes IB . Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537–3545.
Feldmann M, Maini RN . TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9: 1245–1250.
Burness CB, Duggan ST . Etanercept (SB4): a review in autoimmune inflammatory diseases. BioDrugs 2016; 30: 371–378.
Burmester GR, Pope JE . Novel treatment strategies in rheumatoid arthritis. Lancet 2017; 389: 2338–2348.
Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res 2015; 38: 575–584.
Lopalco G, Rigante D, Giannini M, Galeazzi M, Lapadula G, Iannone F et al. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol 2016; 34: 531–538.
Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A et al. Efficacy and safety of riolonacept (Interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-studies. Arthritis Rheum 2008; 58: 2443–2452.
Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011; 70: 1264–1271.
Cavalli G, Dinarello CA . Treating rheumatological diseases and co-morbidities with interleukin-1 bloking therapies. Rheumatology (Oxford) 2015; 54: 2134–2144.
Jing C, Jianbo W, Yuan L, Rong J, Baoyi L . A new IL-1 receptor inhibitor 139A: fermentation, isolation, physico-chemical properties and structure. J Antibiot (Tokyo) 2003; 56: 87–90.
Zhang Y, Zhou J, Chang M, Bai L, Shan J, Yuan L et al. Characterization of and functional evidence for Ste27 of Streptomyces sp. 139 as a novel spermine/spermidine acetyltransferase. Biochem J 2012; 443: 727–734.
Zhang Y, Wang LF, Bai JY, Guan MZ, Jiang R, Li Y et al. Anti-inflammatory effect of ebosin on rat collagen-induced arthritis through suppressing production of interleukin-1β, interleukin-6 and tumor necrosis factor-α. Eur J Inflamm 2013; 11: 697–708.
Zhang Y, Wang L, Bai L, Jiang R, Guo L, Li Y et al. Effect of ebosin on modulating interleukin-1β-induced inflammatory responses in rat fibroblast-like synoviocytes. Cell Mol Immunol 2016; 13: 584–592.
Mayer-Barber KD, Yan B . Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell Mol Immunol 2017; 14: 22–35.
Jo EK, Kim JK, Shin DM, Sasakawa C . Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 2016; 13: 148–159.
Acknowledgements
This research was supported by grants from the Natural Science Foundation of China (No. 30530830 and No. 81302677) and grants from the National Mega-Project for Innovative Drugs (No. 2012ZX09301002-001-023-02 and No. 2014ZX09201001-004-001).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Zhang, Y., Wang, L. & Li, Y. Ebosin: a potential therapeutic agent for rheumatoid arthritis and autoinflammatory syndromes. Cell Mol Immunol 15, 12–14 (2018). https://doi.org/10.1038/cmi.2017.90
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2017.90
This article is cited by
-
Characterization and functional evidence for Orf2 of Streptomyces sp. 139 as a novel dipeptidase E
Applied Microbiology and Biotechnology (2024)